Mark Tidswell to Biomarkers
This is a "connection" page, showing publications Mark Tidswell has written about Biomarkers.
Connection Strength
0.066
-
Da Cruz RS, Teague HL, Ramos-Benitez MJ, Malavez-Cajigas SJ, Williams T, Miao R, Tian X, Lin G, Busse LW, Khan A, Moskowitz A, Hager DN, Rice TW, Ginde AA, Iovine NM, Chen P, Safdar B, Gibbs KW, Javaheri A, de Wit M, Harkins M, Hudock K, Merck LH, Barksdale A, Sturek JM, Schrager H, Shapiro NI, Lanspa M, Harris E, Sellers S, Goodwin AJ, Tidswell MA, Filbin MR, Shotwell MS, Semler MW, Self WH, Collins SP, Strich JR. Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Crit Care Explor. 2026 Jul 01; 8(7):e1405.
Score: 0.041
-
Hotchkiss RS, Colston E, Yende S, Crouser ED, Martin GS, Albertson T, Bartz RR, Brakenridge SC, Delano MJ, Park PK, Donnino MW, Tidswell M, Mayr FB, Angus DC, Coopersmith CM, Moldawer LL, Catlett IM, Girgis IG, Ye J, Grasela DM. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019 10; 45(10):1360-1371.
Score: 0.026